In February 2024, the National Science and Technology Council of the United States released the “Critical and Emerging Technologies List Update for 2024”, listing 18 key emerging technology fields that are particularly important to US national security, including biotechnology, artificial intelligence, advanced computing and other technologies. Among them, synthetic biology ranks first in the sub-field of biotechnology!
As a cutting-edge representative of disruptive innovation and interdisciplinary integration in the field of biology in the 21st century, synthetic biology is highly concerned by governments, academia and industry, and is an emerging key field in the global strategic layout. China's "14th Five-Year Bioeconomy Development Plan” proposed that bioeconomy, including synthetic biology, is a new driving force for China's economic transformation in the future. Synthetic biology, which has been called the third biotechnology revolution, is leading the new wave of science and technology by integrating multiple frontier sciences such as molecular and cell biology, engineering, biochemistry, and information technology.Beijing Biostar Pharmaceuticals Co., Ltd. is a synthetic biology-driven globalized biopharmaceutical company committed to developing innovative drugs in oncology through synthetic biology. In the past over 20 years since establishment, we have built three key synthetic biology-based technology platforms, including the combinatorial biosynthesis, the microbial fermentation production, and the microbial drug formulation development. Our key product Utidelone is produced by genetical engineering bacteria, being the only approved innovative chemotherapy drug developed by synthetic biology technology and standing as exemplary application of synthetic biology in the field of medicine. Using mature and stable platforms, we will continue to complete the construction of different genetically engineered bacteria and the industrialization of multiple candidate molecules, and walk in the forefront of synthetic biology R&D and applications, to address the changing medical needs for the treatment of cancers.Source: https://www.whitehouse.gov华昊中天核心技术-合成生物学被美国《关键和新兴技术清单》列为生物技术领域首位2024年2月，美国家科学技术委员会发布《关键与新兴技术清单（2024年更新版）》，列出对美国国家安全尤为重要的18个关键新兴技术领域，包括生物技术、人工智能、先进计算等技术。其中合成生物学在生物技术的子领域中位列第一！作为21世纪生物学领域颠覆性创新和学科交叉融合的前沿代表，合成生物学受到各国政府、学术界、产业界高度关注，是全球战略布局的新兴重点领域。我国《“十四五”生物经济发展规划》中提出，包括合成生物学在内的生物经济是未来中国经济转型的新动力。被称为“第三次生物技术革命”的合成生物学，深度融合了分子和细胞生物学、工程学、生物化学、信息技术等多个尖端科学，正在引领科技新浪潮。北京华昊中天生物医药股份有限公司是一家合成生物学技术驱动的全球化生物医药公司，致力于利用合成生物学技术开发肿瘤创新药。公司成立至今二十余载，已建立了基于合成生物学的三大关键技术平台：组合生物合成平台、微生物发酵生产技术平台及微生物药物制剂开发平台。其自主研发的核心产品优替德隆乃由基因工程菌生产，是全球唯一由合成生物学技术开发并获批上市的化疗创新药，是合成生物学在医药领域成功应用的典范。利用成熟稳定的技术平台，公司可以持续完成不同基因工程菌的构建和多个候选分子的产业化，走在合成生物学研发和应用前沿，满足不断变化的癌症临床诊疗需求。